Loading
GNAQ (Guanine nucleotide-binding protein G(q) subunit alpha) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Hepatocellular carcinoma, Breast cancer and 3 more.
Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signalling cascades. The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state. Signalling by an activated GPCR promotes GDP release and GTP binding.
CIViC holds 9 clinical evidence items and 0 assertions across 4 variants, naming Vemurafenib, Trametinib, Mirdametinib and PLX4720 and others. Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes affected pathway 0.87, literature 0.87, genetic association 0.03, somatic mutation 0.95, animal model 0.59). IntOGen calls it a driver in 4 cohorts (2 activating, 1 loss-of-function), covering Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Cutaneous Melanoma, Uveal Melanoma. In OnCo, 1 product record names it (Darovasertib).
In plain words · GNAQ (Guanine nucleotide-binding protein G(q) subunit alpha) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Hepatocellular carcinoma, Breast cancer and 3 more.
GNAQ (Guanine nucleotide-binding protein G(q) subunit alpha) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Hepatocellular carcinoma, Breast cancer and 3 more.
Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signalling cascades.
No product in this corpus aims at GNAQ yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Tumour-specific alteration: 1 of 1 medicines aimed at it name a mutant, fusion, exon or hotspot in their mechanism (Darovasertib), an alteration absent from normal cells. HPA GNAQ: RNA low tissue specificity; blood lineage lineage enriched (granulocytes 27 nTPM); no normal tissue stained high; highest cancer staining head and neck cancer (1 of 4 high). Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Skin cancer (all types), Hepatocellular carcinoma, Breast cancer (all types), Lung cancer (all types)); Open Targets associates it with 1 specific cancer type at or above 0.5 (congenital hemangioma). (Rule 4 of scripts/fetch-target-specificity.ts.)
Sources: ClinicalTrials.gov: trials of Darovasertib; Human Protein Atlas GNAQ tissue; Open Targets ENSG00000156052 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Lesch K.-P. et al, Biol. Psychiatry, 1992, "Signal-transducing G proteins and antidepressant drugs: evidence for modulation of alpha subunit gene expression in rat brain". Source.
Sources: HGNC HGNC:4390 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P50148 (protein name, function text, keywords and locations (REST API)); CIViC gene GNAQ (9 evidence items, 0 assertions, 4 variants; diseases: Uveal Melanoma, Skin Melanoma, Congenital Hemangioma (GraphQL API, CC0)); Open Targets ENSG00000156052 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: melanoma 0.72, skin cancer 0.62, ocular melanoma 0.64, breast cancer 0.52 (GraphQL API, CC0)); IntOGen GNAQ (driver in 4 cohorts (Act 2, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signalling cascades. The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state. Signalling by an activated GPCR promotes GDP release and GTP binding. The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the signal. Both GDP release and GTP hydrolysis are modulated by numerous regulatory proteins. Signalling is mediated via phospholipase C-beta-dependent inositol lipid hydrolysis for signal propagation: activates phospholipase C-beta: following GPCR activation, GNAQ activates PLC-beta (PLCB1, PLCB2, PLCB3 or PLCB4), leading to production of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). Location: Cell membrane; Golgi apparatus; Nucleus; Nucleus membrane (UniProt). Locus 9q21.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues. Blood: lineage enriched (granulocytes 27 nTPM).
No normal tissue stained high.
Medium only: breast cancer, carcinoid, cervical cancer, colorectal cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"GNAQ" OR ABSTRACT:"GNAQ" OR TITLE:"G protein subunit alpha q" OR ABSTRACT:"G protein subunit alpha q" OR TITLE:"Guanine nucleotide-binding protein G q subunit alpha" OR ABSTRACT:"Guanine nucleotide-binding protein G q subunit alpha" OR TITLE:"G-ALPHA-q" OR ABSTRACT:"G-ALPHA-q") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GNAQ, not a curated reading list.
Shares Darovasertib, Uveal melanoma, Skin cancer (all types), CIViC.
Shares Darovasertib, Uveal melanoma, Melanoma.
Shares Uveal melanoma, CIViC, IntOGen, Melanoma.
Shares Darovasertib, Uveal melanoma.
Shares Darovasertib, Uveal melanoma.
Shares Uveal melanoma, CIViC, Melanoma, Open Targets Platform.
Shares Uveal melanoma, CIViC, IntOGen.
Shares Darovasertib, Uveal melanoma, Melanoma.